Non-coding Sequences Which Control Transcription Or Translation Processes (e.g., Promoters, Operators, Enhancers, Ribosome Binding Sites, Etc.) Patents (Class 536/24.1)
-
Patent number: 8691965Abstract: The present invention relates to oligonucleotides for modulation of target RNA activity. Thus, the invention provides oligonucleotides that bind to microRNA binding sites of target RNA. The oligonucleotides may activate RNase H or RNAi. In a preferred embodiment, the oligonucleotides prevents a microRNA from binding to its binding site of the target RNA and thereby prevent the microRNA from regulating the target RNA. Such oligonucleotides have uses in research and development of new therapeutics.Type: GrantFiled: June 13, 2008Date of Patent: April 8, 2014Assignee: Mirx Therapeutics ApsInventor: Thorleif Møller
-
Patent number: 8691564Abstract: The present invention provides an insect expression system that may be used to provide biological control of pest insects and control transmission of infectious diseases transmitted to the human population by insects.Type: GrantFiled: June 22, 2012Date of Patent: April 8, 2014Assignee: The Board of Trustees of the University of ArkansasInventor: Helen Benes
-
Patent number: 8692069Abstract: The present invention relates to environmental stress-inducible 557 promoter isolated from rice, a recombinant plant expression vector comprising the promoter, a method of producing a target protein by using the recombinant plant expression vector, a method of producing a transgenic plant using the recombinant plant expression vector, a transgenic plant produced by the method, a method of improving resistance of a plant to environmental stress by using the promoter, and a primer set for amplification of the promoter.Type: GrantFiled: July 26, 2010Date of Patent: April 8, 2014Assignee: GenDocs, Inc.Inventors: Haw Jee Chung, Ju Young Park, Mi Na Kim, Yong Woog Lee
-
Patent number: 8691786Abstract: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded RNA (“dsRNA”), and methods for preparing them, that are capable of reducing the expression of target genes in eukaryotic cells. The dsRNA has a first oligonucleotide sequence that is between 25 and about 30 nucleotides in length and a second oligonucleotide sequence that anneals to the first sequence under biological conditions. In addition, a region of one of the sequences of the dsRNA having a sequence length of at least 19 nucleotides is sufficiently complementary to a nucleotide sequence of the RNA produced from the target gene to trigger the destruction of the target RNA by the RNAi machinery.Type: GrantFiled: January 24, 2013Date of Patent: April 8, 2014Assignees: City of Hope, Integrated DNA Technologies, Inc.Inventors: John J. Rossi, Mark A. Behlke, Dongho Kim
-
Patent number: 8691505Abstract: The problem to be solved by the present invention is to provide a highly-efficient transformation technology, specifically, a highly-efficient promoter used for transforming algae, a vector comprising the promoter, and a method for transforming algae by using the vector. The promoter according to the present invention is characterized in comprising a polynucleotide constituting a non-coding region located upstream of a gene encoding a structural protein of a ClorDNA virus, and the like.Type: GrantFiled: February 10, 2011Date of Patent: April 8, 2014Assignee: Kochi UniversityInventors: Masao Adachi, Takuma Okami, Keizo Nagasaki, Yuji Tomaru
-
Patent number: 8691784Abstract: The present invention is related to a nucleic acid, preferably binding to MCP-1, selected from the group consisting of Type 1A nucleic acids, type 1B nucleic acids, Type 2 nucleic acids, Type 3 nucleic acids, Type 4 nucleic acids and nucleic acids comprising SEQ ID NOs:87-115.Type: GrantFiled: June 4, 2012Date of Patent: April 8, 2014Assignee: NOXXON Pharma AGInventors: Werner Purschke, Florian Jarosch, Dirk Eulberg, Sven Klussmann, Klaus Buchner, Christian Maasch
-
Patent number: 8692071Abstract: The present invention provides non-coding regulatory element polynucleotide molecules isolated from the At.PLD? gene or the At.HVA22e gene of Arabidopsis thaliana and useful for expressing transgenes in plants. The invention further discloses compositions, polynucleotide constructs, transformed host cells, transgenic plants and seeds containing the Arabidopsis thaliana regulatory polynucleotide sequences, and methods for preparing and using the same.Type: GrantFiled: November 23, 2009Date of Patent: April 8, 2014Assignee: Monsanto Technology LLCInventors: Subbaiah Chalivendra, Karen K. Gabbert, Wei Wu
-
Publication number: 20140093884Abstract: The present invention relates to a new process for identifying novel anti-inflammatory molecules with reduced direct transrepression of genes induced by glucocorticoids. The inventors have discovered that GCs-mediated transrepression can be mediated not only via the tethering indirect pathway, but also through direct binding of GR to “simple” negative GREs (nGRE), which belongs to a novel family of evolutionary-conserved cis-acting negative response elements (IR nGREs), and are found in numerous GC-repressed genes.Type: ApplicationFiled: April 13, 2012Publication date: April 3, 2014Applicants: UNIVERSITE DE STRASBOURG, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)Inventors: Pierre Chambon, Daniel Metzger, Milan Surjit
-
Patent number: 8686125Abstract: The invention provides a method for producing a chimeric promoter polynucleotide capable of controlling transcription of an operably linked polynucleotide in a plant cell or plant, wherein the method comprises combining: a) at least one sequence motif comprising a sequence with at least 70% identity to SEQ ID NO:1, 11 or 12, and b) another polynucleotide sequence. The invention also provides chimeric promoters polynucleotides comprising the sequences defined in a) and b). The invention also provides constructs, vectors, host cells, plant cells and plants comprising the chimeric promoter polynucleotides of the invention. The invention also provided methods for modifying gene expression and phenotype of plant cells and plants by transforming the plant cells and plants with the chimeric promoter polynucleotides of the invention.Type: GrantFiled: May 12, 2009Date of Patent: April 1, 2014Assignee: The New Zealand Institute for Plant and Food Research LimitedInventors: Richard Espley, Roger P. Hellens, Andrew C. Allan, David Chagne, Cyril Brendolise
-
Patent number: 8686127Abstract: This invention relates to an agent, a composition and a product comprising at least one apoptosis-inducing substance, and at least one substance which inhibits expression and/or activity of an apoptosis-inhibiting substance; a method for inducing apoptosis or for treating a proliferative disease using one or more of them; a nucleic acid construct comprising a nucleic acid molecule encoding a protein to be expressed and a nucleic acid molecule which inhibits expression of an undesired protein; and a method for expressing a desired protein in a cell while inhibiting the expression of an undesired protein.Type: GrantFiled: April 13, 2009Date of Patent: April 1, 2014Assignee: LSIP, LLCInventors: Masashi Idogawa, Yasushi Sasaki, Takashi Tokino
-
Patent number: 8685720Abstract: The present invention provides compositions and methods for programming mammalian cells to perform desired functions. In particular, the present invention provides compositions and methods for programming stem cells to differentiate into a desired cell type. A quorum sensing systems that regulates the expression of cell fate regulators is introduced into mammalian host cells, such as stem cells. The quorum sensing systems generally comprises vectors that express the components of a bacterial quorum sensing pathway, including proteins which catalyze the synthesis of an autoinducer and a gene encoding a regulatory partner of the autoinducer, and vectors in which genes encoding cell fate regulators are operably linked to a promoter induced by the autoinducer/regulatory partner complex.Type: GrantFiled: November 1, 2007Date of Patent: April 1, 2014Assignee: The Trustees of Princeton UniversityInventors: Ron Weiss, Ihor Lemischka, Priscilla E. M. Purnick, Christoph Schaniel, Miles Miller, Patrick Guye
-
Patent number: 8685940Abstract: Connexin modulation for the treatment of wounds that do not heal at expected rates, including delayed healing wounds, incompletely healing wounds, and chronic wounds, and associated methods, compositions and articles.Type: GrantFiled: November 11, 2011Date of Patent: April 1, 2014Assignee: CoDa Therapeutics, Inc.Inventors: David Laurence Becker, Colin Richard Green, Bradford J. Duft
-
Patent number: 8685937Abstract: The present invention relates to optimized aptamers and methods of using these aptamers.Type: GrantFiled: August 6, 2009Date of Patent: April 1, 2014Assignee: University of Iowa Research FoundationInventors: Paloma H. Giangrande, James O. McNamara, Anton P. McCaffrey
-
Patent number: 8686221Abstract: The present invention relates generally to the field of molecular biology and concerns a method for improving plant growth characteristics relative to wild type plants. More specifically, the present invention concerns a method for increasing yield in plants grown under reduced nutrient availability, relative to corresponding wild type plants, comprising modulating expression in a plant of a nucleic acid sequence encoding a class I homeodomain leucine zipper (HDZip) hox5 polypeptide or a homologue thereof.Type: GrantFiled: April 30, 2008Date of Patent: April 1, 2014Assignee: CropDesign N.V.Inventor: Ana Isabel Sanz Molinero
-
Patent number: 8680256Abstract: The present invention relates to a (first) method for producing inducible and/or repressible expression active linear RNA interference constructs comprising a PCR amplification of a source polynucleotide comprising the inhibitory RNA coding sequence of interest or comprising a PCR amplification of a DNA source comprising a promoter using a reverse primer comprising the inhibitory RNA coding sequence of interest. The present invention furthermore relates to a (second) method for producing inducible and/or repressible expression active linear gene constructs comprising a PCR amplification of a source expression polynucleotide comprising a promoter sequence and the DNA sequence of interest or comprising a PCR amplification using the DNA sequence as a template.Type: GrantFiled: May 25, 2009Date of Patent: March 25, 2014Assignee: King Faisal Specialist Hospital & Research CentreInventor: Khalid S. Abu Khabar
-
Patent number: 8680368Abstract: There is provided an expression method of a target foreign gene in a plant induced by a chemical substance, which comprises a step of activating with copper ions a transcription factor encoded by a foreign gene different from the target foreign gene to induce activation of transcription of the target foreign gene by a region having a promoter function contained in the target foreign gene, wherein a nucleotide sequence encoding said transcription factor is contained in a gene construct which is constructed so as to comprise a nucleotide sequence of a 5?-untranslated region of an arbitrary foreign gene downstream from the region having a promoter function contained in the target foreign gene.Type: GrantFiled: March 7, 2008Date of Patent: March 25, 2014Assignee: Sumitomo Chemical Company, LimitedInventors: Takanori Saijo, Akitsu Nagasawa
-
Patent number: 8679829Abstract: The present invention relates to a sulfolobus expression vector comprising: (a) sulfolobus origin of replication; (b) the genes encoding the structural proteins and the site-specific integrase of SSV1, SSV2 or pSSVx, operatively linked to expression control sequences and a packaging signal; (c) one or more selectable marker gene(s), operatively linked to sulfolobus expression control sequences; and (d) a sulfolobus promoter followed 3? by a restriction enzyme recognition site or a multiple cloning site for insertion of a gene of interest and optionally a 3? regulatory element. Moreover, the present invention relates to a shuttle vector comprising the sequences of the expression vector of the invention and additional sequences for propagation and selection in E. coli, wherein the additional sequences comprise (a) an E. coli on of replication; and (b) a marker for selection in E. coli.Type: GrantFiled: June 2, 2004Date of Patent: March 25, 2014Assignee: B.R.A.I.N. Biotechnology Research and Information Network AGInventors: Christa Schleper, Melanie Jonuscheit, Jürgen Eck, Frank Niehaus, Sonja-Verena Albers, Sabrina Froels
-
Patent number: 8680258Abstract: Provided herein are helper nucleic acids comprising at least one microRNA target sequence of an endogenous, cellular microRNA and a nucleic acid encoding a viral protein, wherein the microRNA target sequence is located in the untranslated or translated region of the nucleic acid encoding the viral protein. Also provided are vector systems, compositions and cells comprising the provided helper nucleic acids and a vector or replicon. Methods of making virus-like replicon particles and populations of virus-like replicon particles (VRP) are also provided.Type: GrantFiled: November 25, 2009Date of Patent: March 25, 2014Assignee: Alphavax, Inc.Inventors: Vernon McNeil Coffield, Kurt I. Kamrud, Jonathan F. Smith
-
Patent number: 8679790Abstract: The invention provides compositions and methods for enhanced gene expression. The invention provides a composition comprising a 28-codon leader sequence operably linked to a desired gene which encodes the desired protein.Type: GrantFiled: January 4, 2011Date of Patent: March 25, 2014Assignee: The Trustees of the University of PennsylvaniaInventors: Joshua B. Plotkin, Grzegorz Kudla
-
Publication number: 20140080125Abstract: The invention relates to the FCGR2B gene and its promoter. In particular, the invention relates to FCGR2B promoters with specific nucleotides at polymorphic sites. Characterization of the nucleotides at polymorphic sites is useful for characterizing the gene and the protein and is useful for determining predisposition or susceptibility to certain diseases and infections in a subject or a population of subjects. Such characterization of the gene or protein is also useful for determining immunoresponsiveness or responsiveness to therapeutic agents in a subject or population of subjects. Thus, disclosed herein are a variety of related nucleic acids, methods and tools.Type: ApplicationFiled: April 9, 2013Publication date: March 20, 2014Applicant: UAB Research FoundationInventors: Robert P. Kimberly, Jeffrey Edberg, Kaihong Su, Jianming Wu
-
Patent number: 8674180Abstract: Novel gene sequences from microalgae are disclosed, as well as novel gene sequences useful in the manufacture of triglyceride oils. Also disclosed are sequences and vectors that allow microalgae to be cultivated on sugar cane and sugar beets as a feedstock. In some embodiments, the vectors are useful for the purpose of performing targeted modifications to the nuclear genome of heterotrophic microalgae.Type: GrantFiled: September 17, 2012Date of Patent: March 18, 2014Assignee: Solazyme, Inc.Inventors: Scott Franklin, Aravind Somanchi, Karen Espina, George Rudenko, Penelope Chua
-
Patent number: 8674084Abstract: The inventions is based on an expression enhancer sequence derived from the RNA-2 genome segment of a bipartite RNA virus, in which a target initiation site in the RNA-2 genome segment has been mutated. Deletion of appropriate start codons upstream of the main RNA2 translation initiation can greatly increase in foreign protein accumulation without the need for viral replication. Also provided are methods, vectors and systems, including the ‘hyper-translatable’ Cowpea Mosaic Virus (‘CPMV-HT’) based protein expression system.Type: GrantFiled: January 8, 2009Date of Patent: March 18, 2014Assignee: Plant Bioscience LimitedInventors: Frank Sainsbury, George Peter Lomonossoff
-
Patent number: 8673875Abstract: The invention provides a method for treating atherosclerosis in a subject in need thereof, including administering an effective amount of microRNA-195 to the subject in need thereof. The microRNA-195 may be packaged in a pharmaceutically acceptable carrier. Moreover, the pharmaceutically acceptable carrier may includes a liposome, lipid particle or viral vector.Type: GrantFiled: December 11, 2012Date of Patent: March 18, 2014Assignee: Kaohsiung Medical UniversityInventors: Suh-Hang Hank Juo, Yung-Song Wang
-
Patent number: 8673631Abstract: The present invention relates to a method of using a dicot intron or elements thereof to enhance transgene expression in plants. The present invention also provides constructs, transgenic plants and seeds containing the polynucleotide useful for expressing transgene in plants.Type: GrantFiled: October 24, 2011Date of Patent: March 18, 2014Assignee: Monsanto Technology LLCInventors: Stanislaw Flasinski, Christopher Hubmeier, Maolong Lu, Marianne Malven, Wei Wu
-
Patent number: 8673871Abstract: The present disclosure describes short antisense compounds, including such compounds comprising chemically-modified high-affinity monomers 8-16 monomers in length. Certain such short antisense compound are useful for the reduction of target nucleic acids and/or proteins in cells, tissues, and animals with increased potency and improved therapeutic index. Thus, provided herein are short antisense compounds comprising high-affinity nucleotide modifications useful for reducing a target RNA in vivo. Such short antisense compounds are effective at lower doses than previously described antisense compounds, allowing for a reduction in toxicity and cost of treatment. In addition, the described short antisense compounds have greater potential for oral dosing.Type: GrantFiled: May 7, 2007Date of Patent: March 18, 2014Assignee: Isis Pharmaceuticals, Inc.Inventors: Sanjay Bhanot, Richard S. Geary, Robert McKay, Brett P. Monia, Punit P. Seth, Andrew M. Siwkowski, Eric E. Swayze, Edward Wancewicz
-
Patent number: 8669108Abstract: The invention provides the isolated promoter polynucleotide sequence of SEQ ID NO:1, and fragments and variants thereof. The invention also provides constructs, plant cells and plants genetically modified to contain the promoter polynucleotide. The invention also provides methods for producing plants with altered gene expression and traits via genetic transformation of plants with the promoter polynucleotides.Type: GrantFiled: March 30, 2009Date of Patent: March 11, 2014Assignee: Vialactia Biosciences (NZ) LimitedInventors: Sathish Puthigae, Jonathan Robert Phillips, Nimali Piyushika Withana, Claudia Jeannette Smith-Espinoza, Catherine Jane Bryant, Kerry Robert Templeton, Shivendra Bajaj
-
Patent number: 8669051Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.Type: GrantFiled: August 20, 2007Date of Patent: March 11, 2014Assignee: Intrexon CorporationInventors: Subba Reddy Palli, Mohan Basavaraju Kumar, Dean Ervin Cress, Ted Tsutomu Fujimoto
-
Publication number: 20140068813Abstract: Described are synthetic promoters capable of mediating gene expression in plants upon pathogen infection. Furthermore, recombinant genes and vectors comprising said chimeric promoters as well as host cells transformed with such chimeric promoters, recombinant genes, or vectors are provided. Additionally, diagnostic compositions and kits comprising such chimeric promoters, recombinant genes, vectors or cells are described. Provided are further methods for the identification of compounds being capable of activating or inhibiting genes that are specifically expressed in plants upon pathogen infection employing the above described means. Furthermore, transgenic plant cells, plant tissue, and plants containing the above-described chimeric promoters, recombinant genes, and vectors as well as the use of the aforementioned chimeric promoters, recombinant genes, vectors and/or compounds identified by the method of the invention in plant cell and tissue culture, plant breeding, and/or agriculture are described.Type: ApplicationFiled: June 28, 2013Publication date: March 6, 2014Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.Inventors: Christoph Kirsch, Elke Logemann, Klaus Hahlbrock, Paul Rushton, Imre Somssich
-
Publication number: 20140065666Abstract: Isolated polynucleotides comprising a CLDN5 mini-promoter are provided. The mini-promoter may be operably linked to an expressible sequence, e.g. reporter genes, genes encoding a polypeptide of interest, regulatory RNA sequences such as miRNA, siRNA, anti-sense RNA, etc., and the like. In some embodiments a cell comprising a stable integrant of an expression vector is provided, which may be integrated in the genome of the cell. The mini-promoter may also be provided in a vector, for example in combination with an expressible sequence. The polynucleotides find use in a method of expressing a sequence of interest, e.g. for identifying or labeling cells, monitoring or tracking the expression of cells, etc.Type: ApplicationFiled: January 29, 2013Publication date: March 6, 2014Applicant: THE UNIVERSITY OF BRITISH COLUMBIAInventor: The University of British Columbia
-
Patent number: 8664189Abstract: The present invention relates to RNAi constructs with improved tissue and cellular uptake characteristics and methods of use of these compounds in dermal applications.Type: GrantFiled: September 22, 2009Date of Patent: March 4, 2014Assignee: RXi Pharmaceuticals CorporationInventors: Anastasia Khvorova, William Salomon, Joanne Kamens, Dmitry Samarsky, Tod M. Woolf, Pamela A. Pavco, James Cardia
-
Patent number: 8663657Abstract: A nucleic acid construct comprising a chimeric promoter sequence and a cloning site for insertion of a coding sequence in operable linkage with the chimeric promoter, wherein the chimeric promoter sequence comprises: (a) a hCMV immediate early promoter sequence; (b) exon 1 and at least a part of exon 2 of the hCMV major immediate early gene; and (c) a heterologous intron provided in place of the intron A region of the hCMV major immediate early gene.Type: GrantFiled: October 11, 2004Date of Patent: March 4, 2014Assignee: PowderJect Vaccines, Inc.Inventor: James Fuller
-
Patent number: 8664188Abstract: No antiviral regimen has been consistently successful in treating H5N1 virus infection. We demonstrate that a group of highly effective siRNAs targeting different H5N1 viral genes shares a unique motif, GGAGU/ACUCC. We further demonstrate that the effectiveness of siRNAs containing this motif is not sequence specific. The results suggested that the structure of the unique motif is critical in determining the potency of siRNA-mediated protective effects against viral infection and this potent in vivo protection is associated with early productions of ?-defensin and IL-6 induced by the motif. Provided are methods and prophylactic and therapeutic agents useful against other viral infections in addition to the H5N1 influenza virus.Type: GrantFiled: December 11, 2009Date of Patent: March 4, 2014Assignee: Xiangxue Group (Hong Kong) Company LimitedInventors: Bojian Zheng, Hongyan Sui, Yongping Lin
-
Publication number: 20140057968Abstract: Methods and compositions are disclosed for controlling expression of TNF receptors (TNFR1 and TNFR2) and of other receptors in the TNFR superfamily using compounds that modulate splicing of pre-mRNA encoding these receptors. More specifically these compounds cause the removal of the transmembrane domains of these receptors and produce soluble forms of the receptor which act as an antagonist to reduce TNF-? activity or activity of the relevant ligand. Reducing TNF-? activity provides a method of treating or ameliorating inflammatory diseases or conditions associated with TNF-? activity. Similarly, diseases associated with other ligands can be treated in like manner. In particular, the compounds of the invention are splice-splice switching oligomers (SSOs) which are small molecules that are stable in vivo, hybridize to the RNA in a sequence specific manner and, in conjunction with their target, are not degraded by RNAse H.Type: ApplicationFiled: March 11, 2013Publication date: February 27, 2014Inventors: Peter L. Sazani, Ryszard Kole, Henrik Orum
-
Patent number: 8658778Abstract: Promoters that include a tissue-selective promoter sequence and a second promoter sequence operatively coupled to the tissue-selective promoter sequence, wherein the second promoter sequence includes a minimal viral promoter sequence, are disclosed. Nucleic acids and compositions that include these promoter sequences are also disclosed. Also disclosed are methods of improving the function of a tissue-selective promoter, involving operatively coupling a tissue-selective promoter sequence with a second promoter sequence that includes a minimal viral promoter sequence. Also disclosed are methods of delivering a gene into a cell, methods of treating a subject with a hyperproliferative disease, and methods of imaging a cell that involve use of the novel promoter sequences set forth herein.Type: GrantFiled: March 9, 2006Date of Patent: February 25, 2014Assignee: Board of Regents, The University of Texas SystemInventors: Lin X. Ji, Bingliang Fang, Jack A. Roth
-
Patent number: 8658155Abstract: Methods and compositions for producing selected non-human mammalian germ cells and gametes and for making non-human animals using the produced germ cells and gametes are provided by the present invention. Methods of generating a non-human embryo and/or animal derived from donor stem cells, methods of generating chimeric non-human animals having substantially all gametes and/or germ cells derived from the donor stem cells, methods of producing a non-human host embryo lacking functional endogenous germ cells and non-human host embryos incapable of developing endogenous gametes of the present invention are described herein.Type: GrantFiled: December 27, 2011Date of Patent: February 25, 2014Assignee: The Jackson LaboratoryInventors: Michael V. Wiles, Robert Taft
-
Patent number: 8658779Abstract: A transcriptional regulatory region of perilla anthocyanin 3-acyltransferase is useful for altering the flower color of plants.Type: GrantFiled: March 9, 2010Date of Patent: February 25, 2014Assignee: Suntory Holdings LimitedInventors: Yoshikazu Tanaka, Masako Mizutani
-
Patent number: 8658363Abstract: According to one embodiment, a cell for measuring a level of Ah receptor transcriptional activation is provided. The cell is derived from a neural cell. The cell contains a chromosome into which a reporter construct and an Ah receptor gene are introduced. The reporter construct has a sequence represented by SEQ ID NO: 1 and a reporter gene operably linked to the downstream of the nucleotide sequence. The sequence represented by SEQ ID NO: 1 has a recognizing sequence of an Ah receptor and a nucleotide sequence which is operably linked to the downstream of the recognizing sequence and required to initiate transcription.Type: GrantFiled: March 26, 2012Date of Patent: February 25, 2014Assignee: Kabushiki Kaisha ToshibaInventors: Seiko Yoshimura, Saeko Uruno, Eiichi Akahoshi, Mitsuko Ishihara
-
Publication number: 20140050748Abstract: The present invention provides a mutant CD83 promoter comprising the promoter/enhancer regions of human CD83 promoter and being dendritic cell-specific, and the use thereof, specifically for the treatment or prevention of diseases or medical conditions related to malignancy, autoimmunity or prevention of transplant rejections.Type: ApplicationFiled: April 27, 2012Publication date: February 20, 2014Applicant: FRIEDRICH-ALEXANDER-UNIVERISTAT ERLANGEN-NURNBERGInventors: Alexander Steinkasserer, Marcello Stein, Thomas Werner, Ilka Knippertz
-
Patent number: 8653249Abstract: The present inventors successfully constructed expression vectors that enable high-level production of foreign gene-derived proteins in mammalian host cells, which comprise a translation-impaired drug resistance gene cistron whose expression has been attenuated by altering the codons to the least frequently used codons in mammals; and a gene cassette which has a cloning site for incorporation of a foreign gene between a highly transcriptionally active promoter and a highly stable polyadenylation signal.Type: GrantFiled: February 27, 2009Date of Patent: February 18, 2014Assignees: Fuso Pharmaceutical Industries, Ltd., National University Corporation Hokkaido UniversityInventors: Yasuhiko Suzuki, Keiichi Yamamoto, Hiroshi Tahara, Yusuke Suzuki
-
Patent number: 8648228Abstract: Nucleotide sequences of a Msca1 gene, critical to male fertility in plants are described, with DNA molecule and amino acid sequences set forth. Promoter sequences and their essential regions are also identified. The nucleotide sequences are useful in impacting male fertility in plants.Type: GrantFiled: February 7, 2011Date of Patent: February 11, 2014Assignees: Pioneer Hi Bred International Inc, E I du Pont de Nemours and CompanyInventors: Marc C. Albertsen, Tim Fox, Mary Trimnell, Yongzhong Wu, Keith Lowe, Bailin Li, Marianna Faller
-
Patent number: 8648230Abstract: Regulatory regions are shown which regulate expression of an operably linked heterologous nucleic acid molecule in plants. Promoters are described which express at lower levels in pollen cells that in other plant cells. Methods of using such promoter to regulate expression of an operably linked nucleic acid molecule are described. A polyadenylation nucleotide sequence from soybean is further shown.Type: GrantFiled: March 18, 2011Date of Patent: February 11, 2014Assignee: MS Technologies, LLCInventors: Bruce Held, Vaithilingam Sekar, Janell C. Eby, Carol J. Lewnau, Penny Perkins
-
Patent number: 8648051Abstract: The present invention provides a method for inhibiting the proliferation of malignant and/or hyperplastic cells in a subject by administering to the subject a therapeutically effective amount of a guanosine rich oligonucleotide. The present invention also provides oligonucleotides which are capable of being specifically bound to a specific cellular protein which is nucleolin and/or nucleolin in nature, which is implicated in the proliferation of cells, specifically malignant and/or hyperplastic cells, and a method for their selection.Type: GrantFiled: October 29, 2004Date of Patent: February 11, 2014Assignee: Advanced Cancer Therapeutics, LLCInventors: Donald M. Miller, Paula J. Bates, John O. Trent
-
Patent number: 8648229Abstract: The present invention relates generally to transcriptional control sequences for effecting expression of a nucleotide sequence of interest in a plant. More particularly, the present invention relates to transcriptional control sequences that direct specific or preferential expression of an operably connected nucleotide sequence of interest in a plant seed or one or more particular cell or tissue types therein.Type: GrantFiled: September 12, 2008Date of Patent: February 11, 2014Assignee: Australian Centre for Plant Functional Genomics PTY LtdInventors: Sergiy Lopato, Nataliya Kovalchuk, Ainur Ismagul, Jessica Anne Smith
-
Patent number: 8648186Abstract: The invention relates to antisense oligonucleotidic sequences (ODN) against Smad7 suitably modified, and their uses in medical field as therapeutic biological agents, in particular in the treatment of chronic inflammatory bowel disease, such as Crohn's disease and ulcerative colitis.Type: GrantFiled: March 15, 2013Date of Patent: February 11, 2014Assignee: Nogra Pharma LimitedInventor: Giovanni Monteleone
-
Patent number: 8648183Abstract: It is intended to provide base sequences participating in the regulation of the expression of a promoter. It is also intended to modify a promoter based on the base sequence data to give a modified promoter having a high expression activity. Namely, a modified promoter constructed by inserting a first DNA fragment containing CCAATNNNNNN (SEQ ID NO:1) (a first base sequence) and a second DNA fragment containing CGGNNNNNNNNNGG (SEQ ID NO:2) (a second base sequence) into a promoter functioning in a filamentous fungus, wherein N in the base sequence denotes A (adenine), G (guanine), C(cytosine), or T (thymine).Type: GrantFiled: February 28, 2003Date of Patent: February 11, 2014Assignee: Amano Enzyme Inc.Inventors: Kanako Suzuki, Norihiro Tsukagoshi
-
Patent number: 8648184Abstract: The present invention relates to a zearalenone-inducible promoter originated from Gibberella zeae, recombinant vectors comprising the promoters, methods of producing proteins and detecting plants contaminated with zearalenone. The promoter of the present invention can be used for studying essential genes in fungus, characterizing the mechanism of self/nonself recognition in G. zeae, engineering of plant systems to generate plants that can recognize a G. zeae attack and detecting ZEA contamination as a biosensor.Type: GrantFiled: December 13, 2010Date of Patent: February 11, 2014Assignee: SNU R&DB FoundationInventors: Yin Won Lee, Jung Kwan Lee, Ae Ran Park, Seung Hoon Lee, Ho Kyung Son
-
Publication number: 20140038233Abstract: There is provided an expression vector for animal cell having an increased gene expression efficiency, and particularly, an expression vector for animal cells including a MAR element and a SAR element, which are gene expression increasing factors, at a 5? end of a promoter, a 3? end of a transcription termination site, or at both of the 5? end of the promoter and the 3? end of the transcription termination site. The expression vector for animal cells according to the present invention exhibits remarkably increased gene expression efficiency as compared to conventional expression vectors for animal cells, such that protein expression of foreign genes may be significantly increased using this expression vector for animal cells. Particularly, the expression vector for animal cells according to the present invention may be useful in that a high-expression cell line may be secured even without MTX amplification.Type: ApplicationFiled: March 30, 2012Publication date: February 6, 2014Applicant: PANGEN BIOTECH INC.Inventors: Jaeseung Yoon, Kwanghee Baek, Taeho Byun, JeongSoo Park
-
Publication number: 20140038234Abstract: A short human genomic nucleotide sequence from the SAR3 region of the human interferon ?2 gene permits enhances expression stability in the absence of drug selection and permits generation of stable clones or stable pools of cells for producing recombinant proteins. Although stable clones may be generated, the ability to generate stable pools reduces the burden of generating stable clones.Type: ApplicationFiled: March 20, 2012Publication date: February 6, 2014Applicant: National Research Council of CanadaInventor: Yves Durocher
-
Publication number: 20140041080Abstract: Described are synthetic promoters capable of mediating gene expression in plants upon pathogen infection. Furthermore, recombinant genes and vectors comprising said chimeric promoters as well as host cells transformed with such chimeric promoters, recombinant genes, or vectors are provided. Additionally, diagnostic compositions and kits comprising such chimeric promoters, recombinant genes, vectors or cells are described. Provided are further methods for the identification of compounds being capable of activating or inhibiting genes that are specifically expressed in plants upon pathogen infection employing the above described means. Furthermore, transgenic plant cells, plant tissue, and plants containing the above-described chimeric promoters, recombinant genes, and vectors as well as the use of the aforementioned chimeric promoters, recombinant genes, vectors and/or compounds identified by the method of the invention in plant cell and tissue culture, plant breeding, and/or agriculture are described.Type: ApplicationFiled: June 28, 2013Publication date: February 6, 2014Applicant: MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V.Inventors: Christoph Kirsch, Elke Logemann, Klaus Hahlbrock, Paul Rushton, Imre Somssich
-
Patent number: RE44760Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of apolipoprotein B. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding apolipoprotein B. Methods of using these compounds for modulation of apolipoprotein B expression and for treatment of diseases associated with expression of apolipoprotein B are provided.Type: GrantFiled: September 27, 2012Date of Patent: February 11, 2014Assignee: Genzyme CorporationInventors: Rosanne M. Crooke, Mark J. Graham, Susan M. Freier